Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 22, 2022

Primary Completion Date

April 10, 2024

Study Completion Date

April 10, 2024

Conditions
Prader-Willi Syndrome
Interventions
DRUG

RGH-706

"Capsules~Oral administration"

DRUG

Placebo

"Capsules~Oral administration"

Trial Locations (23)

50

IRCCS Ospedale Pediatrico Bambino Gesù, Roma

168

Fondazione Policlinico Universitario Agostino Gemelli, Roma

10032

Morgan Stanley Children's Hospital of NewYork-Presbyterian, New York

11219

Maimonides Medical Center, Brooklyn

11501

NYU Langone Hospital-Long Island, Mineola

12808

General University Hospital, Prague

16147

Istituto Giannina Gaslini, Genova

28009

Hospital General Universitario Gregorio Maranon-Instituto Provincial de Psiquiatria y Salud Mental, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

29010

Hospital Regional Universitario de Málaga - Hospital General, Málaga

Hospital Universitario Virgen de la Victoria, Málaga

31059

Hôpital Larrey, Toulouse

41013

Hospital Universitario Virgen del Rocío, Seville

44106

University Hospitals Cleveland Medical Center, Cleveland

49933

Centre Hospitalier Universitaire d'Angers, Angers

50139

Azienda Ospedaliero-Universitaria Careggi, Florence

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

69495

Centre Hospitalier Lyon-Sud, Pierre-Bénite

80131

"Azienda Ospedaliera Universitaria Federico II", Napoli

92123

Rady Children's Hospital-San Diego, San Diego

94018

Oasi Maria SS, Troina

03010

Hospital General Universitario Dr. Balmis, Alicante

08208

Parc Taulí Sabadell Hospital Universitari, Sabadell

Sponsors
All Listed Sponsors
lead

Gedeon Richter Plc.

INDUSTRY

NCT05322096 - Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter